- Home
- AIMD vs IMNN Comparison
AIMD vs IMNN Comparison
Compare AIMD & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- IMNN
- Stock Information
- Founded
- AIMD 1984
- IMNN 1982
- Country
- AIMD United States
- IMNN United States
- Employees
- AIMD N/A
- IMNN N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- IMNN Health Care
- Exchange
- AIMD Nasdaq
- IMNN Nasdaq
- Market Cap
- AIMD 11.9M
- IMNN 12.1M
- IPO Year
- AIMD N/A
- IMNN 1985
- Fundamental
- Price
- AIMD $2.33
- IMNN $8.76
- Analyst Decision
- AIMD
- IMNN Buy
- Analyst Count
- AIMD 0
- IMNN 2
- Target Price
- AIMD N/A
- IMNN $210.00
- AVG Volume (30 Days)
- AIMD 134.7K
- IMNN 434.2K
- Earning Date
- AIMD 08-15-2025
- IMNN 08-05-2025
- Dividend Yield
- AIMD N/A
- IMNN N/A
- EPS Growth
- AIMD N/A
- IMNN N/A
- EPS
- AIMD N/A
- IMNN N/A
- Revenue
- AIMD $106,207.00
- IMNN N/A
- Revenue This Year
- AIMD N/A
- IMNN N/A
- Revenue Next Year
- AIMD N/A
- IMNN N/A
- P/E Ratio
- AIMD N/A
- IMNN N/A
- Revenue Growth
- AIMD 13.38
- IMNN N/A
- 52 Week Low
- AIMD $2.00
- IMNN $5.55
- 52 Week High
- AIMD $5.00
- IMNN $47.40
- Technical
- Relative Strength Index (RSI)
- AIMD 36.64
- IMNN 44.74
- Support Level
- AIMD $2.40
- IMNN $6.51
- Resistance Level
- AIMD $2.66
- IMNN $9.42
- Average True Range (ATR)
- AIMD 0.19
- IMNN 1.27
- MACD
- AIMD -0.04
- IMNN 0.45
- Stochastic Oscillator
- AIMD 11.77
- IMNN 40.98
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).